- Published at
- by gurufocus.com
mixed
mixed
Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients
PR NewswireSPRING HOUSE, Pa., March 10, 2025
Topline results also show investigational targeted oral peptide icotrokinra achieved clinical remission rates